1491
ONKOLOGIE3418043010760120167227269329388409453
/8408043010731
Onkologie.9168043010761110147195214263313331375390
2024;18(2):103-1081326804301074487128168182220259283325348362399439481508547586631
/20028043010732
www.onkologiecs.cz48658043010765133201214262311348396415464514532576617652669709748
1081288026012657111170
HLAVNÍ341207012670127198263336370
TÉMA733207012657114204274
Aktuální34136501063873107149187218260277
postavení63436501063373106139175210242283301
CAR95136501063274109
T-lymfocytů10763650106295485118171202243278317351393
v1484365010637
terapii15363650106306298140174192209
non-Hodgkinských176136501063979121149190231271311346364405438473512544586
lymfomů236236501062962116146188242282
LITERATURA34158001234978134189250318368438498567
1.3407400853750
Duell4117410834686122138154
J,5877410832437
Lurati645741083327193127149165
S,8327410833346
Dittrich900741083466386111133150183222
M,11437410835670
et12357410833458
al.1314741083334962
First139874108333487099123
Generation15427410834581121157179213236252291330
Chimeric18947410834180963408410835793114130162
Antigen5228410834179101116155190228
Receptor7718410833570103137176198236257
Display1049841083456187126142174205
Functional12748410833369107140164179217256288304
Defects15988410834681100135168192220
In18388410831553
Key19118410833570101
Signal340941083324785123155170
Pathways523941083356788126177209240267
Upon8029410834483121159
Antigen9749410834179100115154189226
Stimulation.1213941083335469126163179210232247285323336
Blood1562941083355189127166
(Internet).174194108319337193126147185220242261272
2010;116:208834010410833469101133146176204236248284318354390
LP-2088.7501041083326889121155191227240
Available101110410834172105121136169208224259
from:12911041083194179137150
http://www.bloodjournal.org/content/116/21/2088.abstract.14611041083386085124137164185236290344355395411450489529340114108315539111215118319921125027130933536440144046149553355458261564367469973476578782285689292794097410141040106310851118115011741187
2.34012400853550
Sadelain40312410833264102136151182197233
M,64812410835467
Brentjens7271241083355588125146161195232257
R,99612410833548
Rivière1056124108335508297130151184
I.125212410831527
The129112410833271105
basic14081241083387095109141
principles15601241083385974111142157195210244270
of184212410833755
chimeric1909124108331688234013410835690111126157
antigen5091341083316888103141175212
receptor7321341083215485118156178213234
design.9781341083377197111149186199
Cancer118913410833971107139171192
Discov.13931341083445984115151182192
2013;3:388-398.15971341083336697126137171181216249283305336369403415
3.34014400853651
O’Brien4031441083476096117133167205
S,62014410833345
Nastoupil67814410834477103126162200239254270
LJ,9601441083315870
Essell10431441083326086121136151
J,120714410832436
et125514410833456
al.13241441083314759
A1396144108341
First-in-Human1450144108332466794117137153190212258295353385423
Phase18851441083357210434015410832661
1,41415410833443
Multicenter,47015410835492107129144176210248269303324334
Open-Label81715410834686121159182215248287323338
Study11681541083325391130162
of134315410833756
CB-010,14121541083407598135167198210
a1635154108332
Next-Generation168015410834479111135155201236274309340164108320537490127165
CRISPR-Edited5181641083397490122156191212246284299321354394
Allogeneic9241641083415671108148182220254269301
Anti-CD19123716410834179100115137179224255285
CAR-T153416410834082118139169
Cell17161641083397388103
Therapy18311641083337110612715934017410833869
with4211741083506587125
a558174108332
PD-160217410833579102132
Knockout,74717410833473110142172209246268281
in104017410831552
Patients11041741083356688102137174195222
with13381741083506688125
Relapsed/Refractory1475174108335708511615518121525428031635036939142345547851434018410832155
B416184108336
Cell4721841083417591106
Non-Hodgkin59918410834584123145192230270310340357395
Lymphoma101518410833260120159198237296329
(ANTLER136418410831961106141174208244
Study).16281841083335593132165183194
Blood18431841083365290130170
(Internet).340194108319347395129151191226249268280
2022;140:9457-9458.64119410833469103138151182213250263299336369403422458495528563577
Available123919410834172106122137170210226262
from:15221941083194179138151
https://doi.16941941083386085125153165193214250289305318
org/10.1182/blood-2022-168128.3402041083375997123156188200231259290323350390406444483522545575610642677698728760795827857891904
4.34021400853651
Sahillioglu40621410833265104119134149164202241257294
AC,7142141083418093
Schumacher82221410833264102140198230262300335357
TN.11932141083327992
Safety12992141083336685119141175
switches14882141083267894116147185220247
for17492141083185678
adoptive1841214108332711091493402241083223769104
cell459224108331658196
therapy.5702241083216095116149188219229
Curr8152241083397697119
Opin94922410834787103140
Immunol110522410831472130168206244260
(Internet).1380224108319347293127148187222244263274
2022;74:190198.1669224108334681011361481812122242542843203402341083346499113
Available47323410834172105120135167207223258
from:7512341083184078136148
https://www.sciencedirect.com/science/article/pii/S0952791521000893.9202341083375983123149162189209260314367378405438453487526558592631646667702734758772804841899925950982997103210703402441083316591121143167183214230265291328344359385418453488522555588621653683717748779816852887921954967
5.34025400853752
Benmebarek41325410833672111171207247281303338369
M-R,80425410835579117132
Karches9572541083357092124163199227
CH,120525410834186100
Cadilha132625410834175115131147185219
BL,15662541083366983
et167125410833457
al.17502541083324862
Killing1833254108336536884100139179
Mechanisms34026410835490122160193231246272329356
of71026410833757
Chimeric7812641083407893151186207223254
Antigen105026410834179101116155190228
Receptor129226410833570103137176198235257
(CAR)156326410831958101136155
T1733264108332
Cells.17802641083397389104130144
Int19382641083155374
J340274108324
Mol37927410835593109
Sci.504274108332647992
2019;20.61227410833468100130143178212224
6.34028400853652
Spiegel4072841083327187122161196212
JY,6342841083246068
Sahaf71828410833265103136155
B,88828410833548
Hossain95128410834583110136169184222
N,118928410834457
et126228410833456
al.13332841083324860
Elevated14092841083324882115148169203243
Axicabtagene1667284108341748912115419321624828732234029410833772
Ciloleucel4252941083395469107123157195226260275
(CAR-19)71329410831857100135157187217235
Expansion96029410833365104137175201215253291
By126429410833567
Immunophenotyping134329410831572130167204242282320354392430452485525540578616
Is197229410831540
Associated3403041083416995134166181213235269308
with6643041083506688126
Toxicity8063041083326697112144159182215
in103730410831452
Diffuse11043041083466181100139165200
Large13193041083316586124159
B-Cell149330410833659101135151166
Lymphoma.167430410833260119158196235293325338
Blood3403141083355189128167
(Internet).523314108319347293127148187222244263274
2018;132:57681331410833468100131143173203235248283317349
LP-576.11773141083326788122156188201
Available139431410834171104119134167206222257
from:16663141083194178136148
http://18303141083385983123135162183
www.bloodjournal.org/content/132/Suppl_1/576.abstract.34032410835110415716820822426230134035639443245349252453955259061265067670574278080283687489592395698610181045107811151154119412101247127813001334136713991412144614851512153515571590162216461659
7.34033400853643
Murthy39533410835491111134171200
H,60633410834456
Iqbal6733341083155290122136
M,82133410835366
Chavez89833410834076107138171199
JC,11083341083246476
et119533410833354
al.12613341083314557
Cytokine13293341083406690126155171207241
Release15813341083356983117148173207
Syndrome:1799334108332619813615619234034410835792103
Current4573441083407697118151188209
Perspectives.6803441083356889115153188220244258290324350363
ImmunoTargets105734410831472129166203240269296317354388410437
Ther.150834410833371105126136
2019;8:43-52.16573441083356899129141175187221252274307339351
8.34035400853652
Mucha41035410835492124162195
SR,6223541083336882
Rajendram7213541083366884118156196217250307
P.104635410833540
Management110435410835487125157196231289324362384
and150535410833270109
Prevention16313541083365690123157195216232270308
of195735410833756
Cellular-Therapy-Related3403641083407489104142157189211230260300335356389428459481518553569601623657696
Toxicity:10543641083336797113145160182216230
Early13023641083326586102134
and145436410833270109
Late15813641083326587121
Complications.1720364108340771351741902052372703403741083223775113140153
Curr.5093741083407697119129
Oncol.65437410834785117154170183
2023;85237410833569102136148
p.101537410833951
5003-5023.108237410833468104137159193227260295307
9.34038400853650
Jung41138410832563102142
S,57438410833346
Greiner64138410834466101117155191213
J,87538410832437
von93338410833270109
Harsdorf106338410834578100128168207229251
S,133538410833346
et140238410833457
al.14803841083324862
Fatal15633841083326385118134
late-onset17183841083154870105129169208235271294
CAR34039410834083120
T-cell-mediated4803941083335286120136151174233268308324356378412452
encephalitis95339410833473105139179218251266281304320346
after13203941083325176110132
axicabtagene-ciloleucel147339410833264791121451852072402803153533894124464624775163404041083155087120153169
in52940410831452
a601404108332
patient6524041083397294109144182203
with8754041083516689127
large10224041083144768106141
B-cell11834041083355891125141156
lymphoma.135940410831446105144182221279311325
Blood17034041083365290128168
Adv.189140410834179112122
2021;5:3789-3793.34041410833468101133141176187222254287322345378410443476489
10.3404240085366984
Hayden43642410834476106144178216
PJ,6644241083355465
Roddie74242410833573112150165199
C,95342410834053
Bader101842410833568106140161
P,119242410833439
et124342410833456
al.13114241083324759
Management138342410835486123155193228285319357378
of177342410833756
adults184242410833170107122144171
and34043410833270109
children465434108331698499138159193231
receiving7124341083215588121136169185223262
CAR98943410834083119
T-cell11244341083325184118133149
therapy:12884341083226095116149189220233
2021153743410833468101133
best168543410833975102125
practice1825434108339619412615016534044410833165
recommendations4174441083215588124182240275313352384405421458497523
of95344410833756
the10224441083215994
European11294441083336990127166202234271
Society141344410833371103118153175208
for16344441083195678
Blood17244441083365189128167
and190444410833269108
Marrow34045410835487108130167218
Transplantation5744541083325083121147186202234272294326348363401440
(EBMT)10304541083185186141175197
and124245410833270109
the13674541083226095
Joint14774541083256378116138
Accreditation163045410834173104125159199214236269291306344382
Committee34046410834180140200216240265301338
of70046410833859
ISCT7814641083154991128
and93146410833373113
EBMT106646410833471128163
(JACIE)12514641083194687128144178199
and147346410833272113
the16084641083226298
European17294641083337194132174211244284
Haemato.34047410834476111169202223260273
Ann.63147410834179117130
Oncol.77947410834786118155171184
Off.981474108347688797
J.109647410832437
Eur.11514741083326990100
Soc.127047410833270103116
Med.140547410835489129142
Oncol.156547410834786118155170183
England;176747410833270109124156194234246
2022;34048410833468101136148
p.50448410833851
259-275.57048410833469101125156189222234
11.3404940085366678
Asokan43549410834169107138171209
S,66149410833245
Cullin7234941083407691106121159
N,89949410834557
Stein-Thoeringer9734941083335487103140163193232270306327343381420455476
CK,14654941083407590
et157249410833456
al.16444941083324861
CAR-T172149410834083119141171
Cell19084941083407489104
Therapy34050410833372107128161200231
and58750410833270109
the7115041083226095
Gut82150410834482104
Microbiota.94150410835470102123160200215253275308321
Cancers127850410834072110143176197225
(Basel).15185041083195487114149165184195
2023;15.172850410833468101136147178208220
12.3405140085366884
Park4395141083356788119
JH,5735141083246982
Sauter67051410833265103125159180
CS,8665141083407386
Palomba9675141083366783121179218251
ML,123451410835486100
et134951410833456
al.14205141083324860
A1496514108341
Phase155251410833572105131166
II173351410831530
Study17795141083325391130162
of195651410833757
Prophylactic3405241083355693133171202218250282306322354
Anakinra71452410834079111141158195217250
to98452410832158
Prevent10625241083355690122156195216
CRS129852410834075109
and142752410833270109
Neurotoxicity155652410834580118139176198235265281313328350384
in196052410831452
Patients3405341083356789104139177198226
Receiving58253410833570103136152184200238277
CD1987453410834086117147
CAR103753410834083118
T1171534108333
Cell12195341083407490105
Therapy133953410833372107128161200232
for15865341083195678
Relapsed16805341083357085118157184219258
or195453410833759
Refractory3405441083356987108140172195231252285
Lymphoma.63754410833158115153191228285316329
Blood9785441083355087124163
(Internet).1153544108318336990123143181215236255265
2021;138:96.14305441083346799129137166195228240274309321
Available176354410834070102116131162200216249
from:3405541083184078136148
https://doi.org/10.1182/blood-2021-150431.503554108338608412315016318921024528429931235037241043646950151354457260363666370371975779683585888892395598710061036106611011137116912001210
13.3405640085366883
Hanna43856410834476114152185
KS,6385641083357082
Kaur73556410833569106127
H,87756410834557
Alazzeh9495641083415789119150184222
MS,118656410835588100
et130156410833456
al.13725641083324860
Cardiotoxicity14475641083407394132148186207244275290322337360393
Associated185556410834169961343405741083314678100134173
With5325741083577496134
Chimeric6855741083407893150185207222254
Antigen95857410834179101116155190228
Receptor120457410833671103137176198235257
(CAR)-T148057410831857100136155177207
Cell17065741083407489104
Therapy18295741083337210712816134058410833970
for4265841083185677
Hematologic51958410834479137169191228244282322337369
Malignancies:90458410835487102117156194226264296311346373385
A1305584108341
Systematic13625841083326289112146204236258273305
Review.168358410833570103118153204215
Cureus.1914584108340763405941083215592119132
2022;14:e28162.48859410833468101136148178209221256290324356387420433
14.3406040085366984
Rejeski4446041083367185120146176192
K,65660410833549
Wang72460410835890127166
Y,91060410833543
Hansen97260410834577115141176214
DK,12056041083468296
et132060410833557
al.13966041083324760
Applying147560410834181120136167182220259
the17546041083215994
EHA/186860410833377118145
EBMT34061410833367122154
Grading5106141083446597135150187225
for7516141083185576
ICAHT8426141083155597141175
after10326141083325074108128
CAR-T:117661410833981117138167175
Comparative136661410834077134173205225258279293325359
Incidence1740614108315528498136170208239272
and34062410833168105
Association4566241083406792129160174204225239275312
with7796241083506485122
Infections9126241083145168101133155169206243268
and119162410833167105
Mortality.130762410835390110134165179193214246255
Blood15736241083354986123161
Adv.174562410834077108117
2024.18736241083336697128139
15.3406340085366882
Lemoine43563410833165122160176213248
J,69663410832435
Bachy74463410833568100137168
E,92463410833346
Cartron9826341083407394118139176214
G,120963410834356
et127863410833456
al.13476341083314659
Nonrelapse141963410834482120141175190222261287322
mortality175463410835795116140173188203225258
after3406441083315074107127
CAR47964410833981116
T-cell6076441083325082115130145
therapy7646441083215892113145183213
for9896441083185576
large10776441083144666103137
B-cell12266441083355790123138152
lymphoma:139064410831546103141179216273304316
a1718644108331
LYSA17616441083316193133
study1906644108325488534065410833869
from4226541083184077135
the5696541083226094
DESCAR-T67665410834578111152194229251281
registry.9696541083215594109134157178212222
Blood12036541083365189127166
Adv.138265410834178111121
2023;7:6589-6598.151565410833468100135146178188223257291324348385418450484498
16.3406640085366883
Rejeski4346641083356983117142171187
K,63266410833448
Perez6916641083356787120149
A,85166410834154
Sesques9166641083326692129166200225
P,115266410833539
et120266410833455
al.12686641083324658
CAR-HEMATOTOX:133766410834081116137181213267308336381412457493505
a1853664108332
model1896664108357943406741083387388
for4486741083185677
CAR54467410834183119
T-cell-related6826741083335185118133148170192225241273294328367
hematologic106867410833873131163185221237275314329361
toxicity14486741083225989104135150172206
in167367410831553
relapsed/17456741083215570102141167202242268
refractory340684108321547294126158181217238272
large6256841083154767105139
B-cell7786841083355790123138153
lymphoma.94468410831546104143181218276307320
Blood.12786841083355088126165177
2021;138:2499-2513.146968410833468100130138167197230242276308340375397428462492521533
17.3406940085366877
Rejeski4376941083357186121148178194
K,65269410833449
Subklewe72269410833270109140156191243277
M,102069410835468
Aljurf11086941083415772110131153
M,128169410835568
et137069410833456
al.14476941083314760
Immune152769410831573131169207242
effector17906941083345372107140164201222
cell-associated340704108331658197119152179205244277292325347381421
hematotoxicity:78270410833773131164186223245283313329361377399433447
EHA/EBMT125070410833377119147181217272306
consensus157770410833169107134169208235272299
grading189770410833859933407141083385391130
and48771410833169109
best61271410833974101124
practice7537141083386093125149165197230
recommendations.10007141083205487124182240275313352385406422460498524538
Blood15557141083355189127167
(Internet).1739714108318337193126148186221244262273
2023;142:865-877.34072410833570104140152183215249262298334369392429463499505
Available86772410834273107123139172213229265
from:11537241083194281140153
https://doi.org/10.1182/13287241083386086126154167195216253292308322361384423450484517530562590622657684
blood.2023020578.3407341083395593131171184220254287322356389423457491524538
18.3407440085366985
Vercellino4417441083366890121154170185200238276
L,73374410833145
Di79474410834560
Blasi8707441083355183110125
R,101074410833650
Kanoun107574410833569107145183221
S,131274410833245
et137374410833456
al.14457441083324760
Predictive15217441083355589129144176200215248282
factors18197441083185284108145166194
of34075410833859
early4287541083356992109143
progression59975410834063103145167203232260277317357
after9857541083335380116139
CAR115375410834186124
T-cell13057541083345489125142159
therapy14937541083226299122157198232
in175375410831555
relapsed/refractory1837754108321587510915034076410832762103130150185205228261294319357379414
diffuse775764108339557595134161197
large9937641083154870109145
B-cell11597641083366094129145161
lymphoma.134176410831547107148187226286319333
Blood16957641083365291131172
Adv.188876410834181114125
2020;4:5607-5615.34077410833468101135148183195230265300333351385419450480492
19.2140740085366982
Jaeger2239741083245691131166187
U,24437410834455
Bishop2515741083355177115153192
MR,27257410835490104
Salles284674108333668196131158
G,30217410834457
et30957410833457
al.3169741083324760
Myc32467410835586118
Expression33817410833265104126160187214228266305
and37037410833270109
Tumor-Infiltrating21408410833366124163185205221259277294309332353387408424462501
T266284108332
Cells2715841083407490105131
Are2867841083416297
Associated2984841083416996135167183215237271310
with3315841083516689127
Response3463841083357198137176215241276
in37608410831453
Patients2140941083356789104139177198226
(Pts)2382941083185477105122
with2520941083506688127
Relapsed/Refractory2662941083367186118158184219259285322357376398431463487524546580
Diffuse3257941083466181100138165200
Large3472941083326586125159
B-Cell36479410833558101135150166
Lymphoma214010410833160118158196234293325
(r/r2480104108318386181
DLBCL)257510410834678114155186205
Treated27951041083335084116138171211
with30211041083506688127
Tisagenlecleucel31631041083324975108147182220236270303318353391423457472
in365010410831553
the37181041083216095
Juliet2140114108324627792127149
Trial.2310114108332496597112125
Blood24561141083355189128167
(Internet).2644114108318337193126148186221243262273
2020;136:48-49.293811410833468101135148178208242255289325348384418428
Available338711410834171104119135167206222257
from:36641141083184178136148
https://doi.org/10.1182/blood-2020-137045.2140124108338598312315016218920924528329931235037140943646950051354357160263666270271875779583585788892295598910131044107411061139117512081220
20.21401340085367288
Locke224813410833269102132167
FL,24351341083336478
Oluwole253413410834763101153191207242
OO,279713410834795107
Kuruvilla29241341083357394133166182197212245
J,318913410832537
et324613410833557
al.33241341083324760
Association34051341083416996135167183215237252291329
of375513410833757
Metabolic214014410835590113146185224241256288
Tumor244914410833266124163185
Volume26541441083367389127185220
(MTV)289514410831973106147169
and308414410833271110
Clinical32151441083405570109124156189205
Outcomes344014410834886109140177236271299
in375914410831553
Second-Line214015410833370104142182223246281297336373
(2L)25351541083195486106
Relapsed/Refractory26631541083367389123163191228269296334371391414448482507546568604
(R/R)32881541083195785124143
Large34531541083326789129165
B-Cell364015410833660105140156172
Lymphoma214016410833160118158196234293325
(LBCL)24821641083185086127158177
Following26761641083326985100139190205243282
Axicabtagene29751641083417489121154193215248287322360395
Ciloleucel33871641083405570108124159197229263278
(Axi-36821641083186093108130
-Cel)214017410832166101118138
Versus23001741083367193121160188
Standard-of-Care25091741083345690130170204226266289330351372417451473509
(SOC)303917410831953102145166
Therapy322717410833474111133167208241
in349017410831554
ZUMA-7.356617410833984141184207239246
Blood21401841083355190128168
(Internet).2329184108318337293127149187222245264275
2022;140:638-640.262418410833569102137149180211247260296330364387424461497510
Available315418410834172105120136168207223258
from:34331841083184178137149
https://36021841083386084124151163190211
doi.org/10.1182/blood-2022-158492.2140194108338769210514316420322926229330633736439542945549651155058862865068171574878380383486489893596810011013
21.21402040085366981
Nastoupil223320410834476102125162199238253268
LJ,25132041083325870
Jain25962041083245570107
MD,271620410835499110
Spiegel28382041083337186120159194209
JY,30602041083245967
et314020410833355
al.32082041083314659
Axicabtagene32792041083417489120153191213245284318356390
Ciloleucel3682204108340546910721402141083154987118152167
(Axi-cel)23202141083185992107129162195211230
CD19256221410834085116146
Chimeric27212141083397792149184205220252
Antigen298521410834179100115153188226
Receptor322321410833570102136175196233254
(CAR)34902141083185799135153
T-Cell36562141083325193126142157
Therapy214022410833373108129163202234
for23952241083185778
Relapsed/Refractory24942241083367187120159186222262288325361380403436469493530552587
Large31022241083316586125160
B-Cell328322410833659102136152168
Lymphoma:347122410833261120160199237296329341
Real214023410833671103118
World227923410835894116132171
Experience.247123410833366105141163178213252284318330
Blood28222341083365190129169
(Internet).3011234108319347294128150188224246265276
2018;132:91330823410833469101132144175205238250286318
LP-91.36472341083316788124156165
Available214024410834171104120135167206222257
from:24172441083184077136148
http://www.bloodjournal.org/content/132/2584244108338598412313616218323428734135139140744548452453957761563667570772373677479583386088892596498510191057107911061139116912021228
Suppl_1/91.abstract.214025410833270109149164201233255289321330364403430453475508540564577
22.21402640085367287
Locke224026410833168101130164
FL,24172641083326376
Miklos25062641083546999115153179
DB,26982641083458193
Jacobson28042641083245688124163190228266
CA,30832641083398295
et319126410833456
al.32602641083314659
Axicabtagene33322641083407388120152191213246284319357391
Ciloleucel37362641083405521402741083155268102139171204219
as237227410833157
Second-Line24412741083336799136173212234266281319353
Therapy280627410833371106126159197228
for30472741083185576
Large31352741083316485123157
B-Cell330427410833558100133148163
Lymphoma.348027410833158116155193230288320333
N2140284108345
Engl220028410833370109125
J2340284108324
Med.238028410835489129142
2022;386:640-654.253728410833468101136148183218253265301337373397434468503516
23.21402940085357186
Iacoboni22382941083154678114152190228243
G,249329410834356
Navarro256129410834476107139159180217
V,279029410833544
Martín-López284629410835485106130145182204236273311346375
AÁ,32332941083418396
et334229410833355
al.34092941083314659
Recent348029410833569101134171192
Bendamustine368429410833569107214030410833870128166192215231268303
Treatment24633041083324983115137195230268290
Before27723041083357090127149183
Apheresis297430410834180119154175209236251277
Has327030410834476103
a3392304108332
Negative344330410834580119151173189221255
Impact371730410831573214031410833972104128
on228231410833775
Outcomes237131410834786108139176234269296
in268131410831552
Patients27473141083356789104139177199226
With29873141083587496134
Large31353141083326586124159
B-Cell330831410833658101135151166
Lymphoma348831410833159118157196234292325
Receiving214032410833570103137152184200238277
Chimeric24353241083407893150186207222254
Antigen270732410834179101116155190228
Receptor295332410833570103136176198235256
T-Cell32273241083335194128143158
Therapy.340332410833372107128161200232242
J3663324108324
Clin37053241083405570108
Oncol214033410834786118155171
Off23263341083476887
J2428334108324
Am246833410834199
Soc258233410833271103
Clin27013341083405570108
Oncol.282433410834786118155171183
2024;42:205-217.302333410833468101133145179212224260294328350381412442448
24.21403440085367186
Greenbaum22413441083446599135173212245283340
U,259634410834454
Hashmi266534410834476103141198214
H,289334410834457
Elsawy29643441083334874107158192
M,317034410835568
et325234410833457
al.33233441083324760
Prognostic33973441083365693133171209236259274306
Impact371834410831572214035410833871102126
of227835410833756
Comorbidities234635410834076134171192231247285299321336370397
on275535410833775
Outcomes284235410834784107137173230265291
of314635410833655
Patients32143541083346687102136173194222
(pts)34483541083185779106123
with35833541083506587125
Relapsed37203541083357021403641083154786113148187
or234136410833759
Refractory24133641083357089111144177201238259293
Large27193641083326586125159
B-Cell289236410833558101134150165
Lymphoma307036410833260119158197235293325
(r/r3409364108318386180
LBCL)350236410833268109140159
Treated3674364108333508411621403741083225595
with22523741083506689127
Chimeric23963741083407793150185207222254
Antigen266737410834179101116155190228
Receptor291237410833570103137176198235256
T-Cell31853741083335194128144159
Therapy336137410833272107128161200231
(CART).360937410831958101136170192203
Blood21403841083355188126166
(Internet).2318384108318337192125146184219241259270
2022;140:4636-4638.260138410833467100134146176206242255289324358392415451487520554567
Available318138410834070103118133165203219253
from:34473841083184077134146
https://36063841083375882121148160186206
doi.org/10.1182/blood-2022-169452.2140394108338769210514316420322926229330633736439542945549651155058862865068171574878380383486589993596810011013
25.21404040085367287
Jaglowski22414041083245695111149200227257273
S,252840410833245
Hu258740410834482
Z-H,268340410833854100113
Zhang281040410833876108146185
Y,300940410833543
et306640410833456
al.31364041083324860
Tisagenlecleucel32104041083335076109148183221236271304319354392424458473
Chimeric36974041083407893214041410835792113129160
Antigen231341410834179101116154189227
Receptor255341410833570102136175197234255
(CAR)282141410831958100136154
T-Cell29884141083335194127143158
Therapy315941410833271106127160199230
for34024141083185677
Adults349241410834179116132154181
with36864141083516688126
Diffuse21404241083456181100138164199
Large23544241083316586124159
B-Cell252742410833558101135151166
Lymphoma270742410833160118158196234293325
(DLBCL):30464241083196597133174205224236
Real329742410833570102117
World342842410835894116132171
Experience361342410833365105140161177214043410833472104138
from22924341083184077136
the24414341083226095
Center255043410834073111133167188
for27524341083185677
International28434341083155374108129168200222237275313346361
Blood32184341083355189128167
&339943410833972130169181
Marrow359443410835587108130167218
Transplant21404441083335084122149188204237275297
Research24584441083367198133166187219257
(CIBMTR)27364441083185873110165199236255
Cellular30124441083407590106144159192213
Therapy324644410833372108129163202234
(CT)35014441083185894116
Registry.3638444108336711111271532140454108322437786
Blood22394541083355189127166
(Internet).2418454108318337192126147185220242260271
2019;134:766.27024541083346899129142172201236248281313348361
Available307645410834171104119134166205220255
from:33444541083184077135147
https://doi.35034541083385983122149161188208243281296309
org/10.1182/blood-2019-130983.21404641083375997123156188200231259290323350390406444483522545575610641672695726756790826861895907
26.21404740085367187
Yassine22414741083356591118133171206
F,246147410833238
Iqbal25134741083155493126141
M,266847410835568
Murthy275047410835492113138176207
H,297147410834457
et304247410833456
al.31124741083324760
Real318647410833671102118
world331847410835088110125164
experience349647410833466105141162178212251283316
of214048410833756
approved220848410833270109130167198232271
chimeric24914841083316883140174195210242
antigen27454841083316990105143177215
receptor29724841083215486119158179216237
T-cell32214841083325083117132146
therapies33804841083215993114146185200234260
outside36534841083377496123138214049410833872
of222449410833755
clinical2292494108330456097111142175189
trials.2494494108321425788103128141
Curr26484941083397595116
Res27774941083356995
Transl28844941083324981118144159
Med305549410835488127
(Internet).3194494108318337091124144182216238256267
2020;68:159170.3473494108334679913314518021522625528531621405041083346295107
Available225950410834070102117132163201217251
from:25225041083184076133145
https://www.sciencedirect.com/science/2679504108337588212014615818420425430735936939642744247651354557761663165168571674075378482087790392695897210061044107511081133
article/pii/S2452318620300386.2140514108332537893125140175201239254269295328361393426459494525556591625659692726763796830865879
27.21405240085367180
Jacobson22405241083245688125165192230268
C,252852410834053
Locke260152410833169101131166
FL,27875241083326377
Ghobadi288352410834483121161194233248
A,315152410834155
et322652410833456
al.33025241083324760
Long-Term338252410833168107146168198229250309
(≥371052410831960
43779524108334
Year21405341083356698119
and227353410833270109
≥2397534108341
52447534108334
Year)24955341083366798120138
Overall264753410834780115136169184199
Survival28615341083326991125141174206222
(OS)30975341083196598117
By322853410833567
12-33095341083346485
and340853410833270109
24-Month35315341083346689145183222243282
Event-Free21405441083336599137159179213233267303
Survival24635441083337092127143175208224
(EFS):27075441083195285117136148
An287554410834180
Updated297554410834483123155177211251
Analysis324754410834179112127159186201227
of349554410833757
ZUMA-1,357254410833882137179201232241
the21405541083226095
Pivotal22495541083354982119141174190
Study24525541083335492131163
of262955410833756
Axicabtagene26995541083417490122154194216248288322361396
Ciloleucel31085541083405671109125160197230263279
(Axi-Cel)34015541083185992108130173207222242
in365755410831452
Patients37235541083356721405641083223772110131159
(Pts)23185641083185478105122
with24595641083516789127
Refractory26055641083367190112145177201238260294
Large29185641083316486124159
B-Cell309656410833558101134150165
Lymphoma328056410833160118158196234293325
(LBCL).36245641083195086127158178189
Blood21405741083365290130170
(Internet).2331574108318347294128150189224247266278
2021;138:1764.262957410833569103135143174204239252282312344381394
Available304457410834172105121136169209225260
from:33255741083194179138150
https://doi.34965741083386085125152165192213249287303316
org/10.1182/blood-2021-148078.21405841083375997123156188200231259290323350390406444483522545575610642674693723754790826858892905
28.21405940085367288
Schuster224259410833265103140167190224245
SJ,25015941083325769
Tam258459410833260118
CS,27165941083407386
Borchmann28165941083357495126164222255293331
P,316059410833640
et321459410833456
al.32845941083324760
Long-term335859410833168107146168191224246304
clinical367659410833146619911421406041083316479
outcomes22396041083377598129166224259286
of254460410833857
tisagenlecleucel2621604108321366396135170208223258291306341379411444460
in310160410831452
patients31736041083387193108143181203230
with34236041083516689127
relapsed35696041083215571103142169204243
or214061410833759
refractory2219614108320547496129161185222244278
aggressive251761410833170109131165191218233265300
B-cell28376141083355892125141156
lymphomas301361410831546105144183221279312338
(JULIET):33716141083194488120135168204225237
a3628614108332
multicentre,36806141083579511021406241083223769103141162184218230
open-label,238862410833877113151173190222261297312324
single-arm,27316241083264179118133168191223245303316
phase306562410833978110136171
23255624108334
study.33086241083264987126158168
Lancet349562410833165103135168191
Oncol37046241083478621406341083316884
(Internet).2242634108318337193127148187222244263274
2021;22:1403-1415.253363410833569102133141176211223253284320353375406437467497509
Available306063410834172105120135167206222257
from:33356341083184078136148
https://doi.35016341083375983123149162189209245283298311
org/10.1016/S1470-2045(21)00375-2.214064410833759971231561882002312622943253503834144454775105345655996356686867207517668018378709029359579881000
29.21406540085367285
Bachy224065410833568101139169
E,242465410833346
Le248465410833266
Gouill256565410834382120135151166
S,274565410833346
Di280565410834661
Blasi28816541083355183110125
R,302065410833650
et308565410833456
al.31566541083314760
A3230654108341
real-world32866541083215587102124176214235251290
comparison35916541083316812616619821406641083213662101139
of229466410833756
tisagenlecleucel2365664108321376396135170208223258291306341379411445460
and284066410833270109
axicabtagene29636641083326479111144183205238277312350385
ciloleucel3363664108331466199115150188220254269
CAR364766410834082118
T3780664108332
cells2140674108331658196122
in227667410831553
relapsed23436741083215570103142168203243
or260067410833859
refractory2674674108320547396129161185222243277
diffuse2966674108338537392130157192
large31726741083154768106141
B3328674108335
cell3377674108332658196
lymphoma.348767410831547106145183222280312326
Nat21406841083457799
Med.225468410835590129142
2022;28:2145-2154.241268410833468101136148183217229264295327359381412444474509521
30.21406940085367287
Kwon224469410833585122161
M,242169410835568
Iacoboni25066941083144779116155194233248
G,277069410834457
Reguera284469410833570110147182203236
JL,30976941083245670
et318369410833456
al.32566941083324760
Axicabtagene33326941083417490122155194216249288323361396
ciloleucel37446941083314621407041083155571107146180215231
compared239270410833271131171205227263304
to271770410832260
tisagenlecleucel27997041083223865100140176216232268302318354393426461477
for32987041083195880
the34007041083226197
treatment35197041083224480113135195232271293
of214071410833857
aggressive221871410833272111133168195222237270305
B-cell25447141083355993127143158
lymphoma.272371410831547107146185224283316330
Haematologica307471410834477112171204226263280318358374406440
(Internet).3535714108318347294128150189225247266278
2022;108:110-121.214072410833468100135147177208243255284312343366397426457467
Available261972410834171104119134166204220255
from:28867241083184077135147
https://haematologica.org/30467241083375882121148160186207245277312369401423459475513552567598631644682703741766
article/view/haematol.2022.280805.214073410833253789312514017520123424928433535939843046552355557761463064367971374678179382986389893496910031015
31.21407440085366981
Kamdar223974410833568126165198219
M,247574410835568
Solomon25617441083327086124183221259
SR,28387441083326781
Arnason293774410834162100133159198236
J,319074410832537
et324474410833456
al.33187441083314760
Lisocabtagene33957441083314773111144177216238271310345383418
maraleucel214075410835790111144159194232264298313
versus24677541083326687114152178
standard26587541083275083121160192213251
of292375410833756
care29937541083316485119
with31267541083506689127
salvage32667541083266075107140179214
chemotherapy34947541083316910416220022226029521407641083215392123
followed2276764108318567186124175209248
by253776410833970
autologous26197641083326992128144182221259297323
stem29557641083264982140
cell3108764108331648095
transplantation32167641083214275113139178193225263284317338354391430
as365876410833258
second-line372976410832661214077410833168107146168184199237272
treatment24307741083224377109131189224262284
in273277410831553
patients28037741083387193108143181203230
with30527741083506688126
relapsed31977741083205470102141168203243
or345877410833759
refractory3535774108320547496129161185222244278
large3940741083154667104139
B-cell4091741083355790123139153
lymphoma42577410831445103142179217274306
(TRANSFORM):4576741083185389132176208239286321376394405
results4993741083215481117132154181
from5186741083194077134
an53327410833269
interim5414741083145172105126141198
analysi.39408410833169100115146172187199
Lancet41518410833164101132165187
(Internet).435084108318337091124145182217238256267
2022;399:2294-2308.4629841083346799133145179212246259293327360395418448482516550563
Available52048410834171103117132164202217251
from:5467841083194076134145
https://doi.org/10.1016/S0140-6736(22)00662-6.3940941083385983123150162189209245283299312350371409436469500513543575607638663696731762794829853891923958992101110451080109811331169120512401274129413311344
32.39401040085367186
Bishop40421041083355177115153192
MR,424910410835591105
Dickinson43691041083456193123139177203242280
M,466410410835468
Purtill47471041083357293118133149164
D,492610410834556
et499710410833456
al.50681041083324760
Second-Line514310410833368100137176215237270285323358
Tisagenlecleucel55161041083335076394011410833170104141156190222237271308339372387
or433911410833758
Standard44091141083325385122160192212250
Care46711141083397192125
in480811410831552
Aggressive487211410834078116137170196222236268302
B-Cell51861141083355799132147162
Lymphoma.536011410833159116154192230394012410835790103
N4058124108345
Engl411812410833371110125
J4258124108325
Med.429812410835489129142
2021;386:629-639.445512410833569102133141176211246258294327361385422456489500
33.39401340085367186
Houot404113410834482121159181
R,423613410833650
Bachy430013410833669101139169
E,448413410833346
Cartron45451341083397293118140177215
G,477513410834457
et484713410833456
al.49181341083324760
Axicabtagene49931341083407389121154193215248287322360395
ciloleucel540313410833146619911515018839401441083316581
as403714410833258
second-line41121441083266194131169208230247262300335
therapy44631441083226095116149188220
in469914410831553
large47681441083154768106141
B4926144108335
cell4978144108331658095
lymphoma509014410831546105144183221279312
ineligible5418144108315538810311815717239401541083395589
for40451541083195678
autologous41391541083316992128144183222260298325
stem44791541083275083141
cell4636154108331658196
transplantation:47481541083214376114140179195227265287319341356394433445
a5209154108332
phase525615410833978110136171
25443154108334
trial.5493154108322435991106119
Nat39401641083457899
Med406016410835590130
(Internet).4211164108318337293127149188223245264275
2023;29:2593-2601.450716410833469102137148184218231267302334367389421454490522532
Available505916410834172105121136168208224259
from:53391641083184178137149
https://doi.org/10.1038/s41591-023-02572-5.5509164108337598439401741083396578105125161199214227266287325351385416429459491524558584608644674704737769787825857892914951984101910521087110711411153
34.39401840085367388
Sehgal404918410833268106145177192
A,426218410834155
Hoda433718410834482122154
D,451218410834556
Riedell45881841083355186125160176191
PA,47991841083357287
et490618410833456
al.49821841083324860
Lisocabtagene50631841083314673111144176216238270310344383418
maraleucel55011841083578939401941083215672109149182218234
as419919410833361
second-line42841941083276498137177218241259275315351
therapy46601941083226299121156197230
in491419410831555
adults499419410833273113129153182
with52001941083526993133
relapsed53571941083225774108149177214255
or394020410833860
refractory4021204108321557597131164188226248283
large43252041083154769108143
B-cell44892041083365994128144159
lymphoma466920410831548107147186225284317
who500720410835191129
were515720410835287108143
not53212041083387799
intended54412041083155476110149394021410833874114
for40752141083185779
haematopoietic417421410833871107165198220258298337353388411427459
stem46542141083265084143
cell4818214108331668297
transplantation49362141083224377116142182198231269291325347362401440
(PILOT):53972141083195570102148181203215
an394022410833373
open-label,404022410833980118158182200234275313330343
phase441122410834080114143179
24618224108335
study.46812241083275191132166177
Lancet488622410833268108142177201
Oncol511522410834889123162179
(Internet).5322224108319357598134157197234258278291
2022;23:1066-1077.394023410833469102137150185221232262294331367390422454487522528
Available448923410834172105121136169208225260
from:47702341083184178137150
https://doi.org/10.1016/49412341083375984124151164191212248287302315354376415441475506519550582615646672
S1470-2045(22)00339-4.39402441083326394126159183214248285317335369404422457493526559592616652665
35.39402540085367186
Ayuk404425410834171109139
F,420125410833339
Gagelmann425825410834376115150166223256294332
N,460825410834457
von468325410833270108
Tresckow48092541083335084111143173210262
B,508925410833548
et515525410833456
al.52292541083324760
Real-world530725410833570102118140192229251267306
results39402641083215582119134156184
of413926410833756
CAR421026410834082118
T-cell43432641083325184118134149
therapy45062641083226095116149189220
for47402641083195678
large48332641083144768106141
B-cell49882641083365992126141157
lymphoma515926410831547105145183221280312
with54862641083506688126
CNS394027410834085117
involvement:40762741083155384122138170204262297335357370
a4466274108331
GLA/DRST451727410834375119146193229263297
study.48332741083265088127159169
Blood50212741083355189128167
Adv520727410834180112
(Internet).5339274108318337193126148186221244262273
2023;7:5316-5319.39402841083346799134145177187221254284315337371403434463474
Available442628410834170103117132164202218252
from:46902841083184077134146
https://doi.org/10.1182/bloodadvances.2023010336.48482841083375882121147159185205240278293305343364401427459490502533560590623649689704742394029410833777109148181214252284318344358394428461496530562594627660694707
36.39403040085367288
Cook404430410834077116146
MR,420630410835490104
Dorris432630410834584105127143169
CS,45103041083407487
Makambi461230410835587117151209248263
KH,48913041083358193
et500030410833456
al.50723041083314760
Toxicity51473041083336797113144160182216
and537830410833270109
efficacy550330410833352708839403141083316597131
of409231410833857
CAR417031410834083120
T-cell43103141083335286120136151
therapy44823141083226196117151190222
in472531410831553
primary47993141083396177135168189224
and504331410833271110
secondary51743141083276295132171211244265299
CNS549431410834086119
lymphoma:394032410831549110151191231292326339
a4304324108333
meta-analysis436132410835996120154178212252286302335364380407
of479332410833859
128487732410833566102
patients.50033241083407598114151191213243257
Blood52853241083365393134175
Adv.548532410834282116127
2023;7:32-39.394033410833468101136147180190225258278311344355
37.39403440085367079
Jacobson40393441083245688125165192230268
CA,43273441083408296
Falvey44433441083326277110144175
C,463834410834053
Bouvier471034410833574112145160195216
R,494634410833549
et501434410833457
al.50903441083324760
A5169344108341
Pilot52303441083354965103125
Study53743441083335492131163
of555634410833756
Axicabtagene39403541083417389121153192214247285320358393
Ciloleucel43453541083405570108124158196228261277
(axi-cel)4635354108318488095117150184199219
for48663541083195677
the49563541083226094
Treatment50633541083335084115137194229267288
of536435410833756
Relapsed/Refractory54333541083357086118157394036410832661100126163198217239272304328365386420
Primary43733641083355671129161182216
and460236410833269108
Secondary472336410833368100137175214246267301
Central503736410834074112133155187203
Nervous525336410834479100135172210236
System55023641083336289394037410832155112
Lymphoma406537410833159117156194232290322
(CNSL).439937410831957102134164183194
Blood46063741083355088126165
(Internet).4784374108318337192125146184219241260270
2022;140:1060-1061.506737410833468100134146176207242255285316351386410440471507536546
Available394038410834171104120135167206222257
from:42123841083194178136148
https://doi.org/10.1182/blood-2022-165256.4376384108337598312314916218920924528329831134937140943546850051254357160263566270271875679583485788892295598910101041107211061139117412081221
38.39403940085367491
Chavez405339410834079113145181211
JC,42873941083246680
Dickinson43893941083466295127144183210250289
M,470139410835469
Munoz479239410835594133173202
JL,50163941083245872
et511039410833558
al.51903941083324962
3-Year52753941083345791123156178
Analysis5475394108341811143940404108315497895123
of408740410833859
ZUMA-12:417040410833885142187210243275289
A4483404108342
Phase454940410833676110139176
24748404108336
Study48074041083345797138173
of500340410833960
Axicabtagene50864041083437895129164206230265306343384421
Ciloleucel55314041083415839404141083155573110149183219236
(Axi-Cel)41994141083196297114138183219236257
As447941410834271
First-Line45734141083335073102126148183200239276
Therapy487241410833475112135170211244
in513941410831555
Patients52174141083367093110147187210239
with54794141083526993133
High-Risk394042410834562103144168207225253285
Large42484241083336891132169
B-Cell444042410833761107143160177
Lymphoma464042410833363125166207248309343
(LBCL).50074241083195391134168189201
Blood52324241083365494135177
(Internet).543342410831935769913515839404341083387396116127
2023;142:894.408643410833469102138150181213246259295330366379
Available448443410834172105121137170210227262
from:47654341083184179138151
https://doi.org/10.1182/49344341083376085125152166193214251289306319358380419446480512525557585617651678
blood-2023-174510.39404441083395594133174197228263297332355386416448481513545558
39.39404540085367286
Ghione40424541083448399137177212
P,427045410833641
Palomba43274541083356884123182221255
ML,459845410835588102
Ghesquieres471645410834483119146186224240276298332360
H,509245410834458
et516645410833457
al.52394541083324861
Treatment53174541083325085117140199234273295
patterns39404641083407598124160183223251
and421446410833373114
outcomes435146410833979103136175235273301
in467546410831555
relapsed/refractory47534641083215774109150178215257285306342363387422456482521544580
follicular5356464108319597693109143183200234256
lymphoma:394047410831547107146186225284317330
results42864741083215683121137160189
from44924741083184179138
the46474741083216096
international47604741083145375109131171204226242281320353369
SCHOLAR-5514647410833274119167200244281303338
study.5501474108326508939404841083397283
Haematologica404648410834578115175208232270287327368384418452
(Internet).4521484108318357497132155195232255275287
2022;108:822-832.483148410833570105141154186219256269306341377398436471505519
Available537348410834173108124140174215394049410831552
from:40144941083194281142155
https://haematologica.org/article/view/haematol.2022.281421.41924941083386187128156170198220261295331391425448487504544585602635670684724747787814846869895912945962998102610601077111311661191123212661303136313973940504108322597690126161195230243280314347379412444454
40.39405140085367489
Rodgers404951410833574113152187208236
TD,43055141083327990
Casulo44155141083407399136152190
C,462551410834053
Boissard46985141083357489115142175196234
F,495251410833338
et501151410833356
al.50875141083324760
Early51675141083326587102134
Relapse53215141083367186118157184219
in556051410831553
First-Line3940524108332476896119138172187225260
Follicular42165241083326985100115147185200233254
Lymphoma:448652410833159118157196234292325337
A4839524108341
Review489552410833671103119153205
of511552410833857
the51885241083216095
Clinical52985241083405670108123155188204
Implications55175241083157339405341083395570102134156171209248274
and423453410833270109
Available436253410834172105120135167206222257
Mitigation46395341083546992107146178200215253292
and495053410833270109
Management507953410835487125157196231289324362384
Strategies.5482534108333547510839405441083225595110145172185
Oncol413854410834786118155171
Ther432254410833272107128
(Internet).4463544108318337193127148186221244263274
2021;9:329-346.475054410833468101132140176189224257291314347382418431
Available519454410834172105120135167207222257
from:54645441083194178136148
https://doi.org/10.1007/s40487-021-00161-5.39405541083385983123150162189209245283299312350371409436469500513543575611644664688724760796832865884921954985100410411077110911401170118912231235
41.39405640085366881
Fowler403456410833269120136171192
NH,423956410834489102
Dickinson43535641083466193123139177203241280
M,464556410835568
Dreyling472656410834567101132148163201240
M,497856410835568
et505956410833456
al.51285641083324760
Tisagenlecleucel5201564108332497510814718121923526930231735239039405741083316581
in404057410831452
adult411257410833171108123146
relapsed42775741083215570103142169204243
or453957410833859
refractory4618574108320547396128161185222243277
follicular4915574108318567287102134171187219240
lymphoma:517457410831547106145183222280312324
the55185741083216095
phase394058410833977109136171
24126584108335
ELARA417658410833264107143186
trial.4377584108322435991106119
Nat45125841083447798
Med.462658410835489129142
2022;28:325-332.478358410833468101136148183217229265297332354387419452465
42.39405940085367086
Jacobson40425941083245688125165192230268
CA,43265941083408397
Chavez443959410834078110141176205
JC,46605941083246578
Sehgal475459410833368106145177193
AR,49625941083417791
et506959410833456
al.51415941083324760
Axicabtagene52175941083417490122154194216249288322361396
ciloleucel39406041083324762101117153191224258274
in423460410831554
relapsed43096041083205571104143170206246
or457660410833759
refractory4656604108321567598131164188226248282
indolent49596041083155393132148183222244
non-Hodgkin522360410833877116139185224264304334351390
lymphoma394061410831548109149189229289323
(ZUMA-5):428461410831959105161204227262281294
a4600614108332
single-arm,46546141083274281122138174198232254314328
multicentre,500361410835998114138154187222261284306342354
phase537961410833979113141177
25577614108335
trial.3940624108322435991106119
Lancet407462410833165103135169191
Oncol428062410834786118155171
(Internet).4466624108318337193126148186221244262273
2022;23:91-103.475462410833469101136149184218230265297316346378411423
Available519262410834172105120135167207222257
from:54646241083194178136148
https://doi.org/10.1016/S1470-2045(21)00591-X.3940634108338598312315016218920924528329931235037140943646950051354357560763866369672675879082384787791294898199810321064107811131149118312161248126613031317
43.39406440085377388
Morschhauser405064410835595117145178217256289327354390412
F,448364410833340
Dahiya454464410834679118134166200
S,476564410833347
Palomba48336441083356884123183223257
ML,511164410835588102
et523464410833558
al.53136441083324862
TRANSCEND539664410833371115161194394065410834073117163
FL:41176541083326377
PHASE420865410833579120154186
24408654108334
STUDY445665410833266112158191
RESULTS466165410833569103146178207241
OF491665410834780
LISOCABTAGENE50106541083314679126167210246279317359393437471
MARALEUCEL549465410835597394066410833680112146190232265297
(LISO-CEL)42586641083195167100148173216250282301
IN458066410831561
PATIENTS466266410833674103120154200234269
(PTS)49526641083195589124143
WITH511666410835875109156
RELAPSED/529366410833670102146182216249295319
REFRACTORY394067410833569102137180220255302338374
(R/R)43346741083195583119138
FOLLICULAR449367410833280112145160201245277321357
LYMPHOMA487067410833263118154198246301344
(FL).52346741083195183102113
Hematol536767410834580138171192230246
Oncol394068410834785117154169
(Internet).4122684108319337192126147185220242261271
2023;41:877-880.440668410833468101135146181211219254287321339375410445457
Available487668410834171104119134166205220255
from:51436841083194178136148
https://doi.53036841083385983122149161188208243281296309
org/10.1002/hon.3196_LBA4.39406941083375997123156188200231262299331358397435474487523553584619656690726767802814
44.39407040085367490
Wang404670410835789127166
M,422870410835468
Munoz431270410835492130168196
J,452470410832436
Goy457670410834483114
A,470670410834155
et477770410833456
al.48497041083324860
Three-Year49257041083337293127163186219250282303
Follow-Up52447041083326985100138190212257296
of555670410833757
KTE-X19394071410833572107129166199229
in419071410831554
Patients42657141083356890106141180202230
With45167141083587598136
Relapsed/Refractory46737141083367288121161188223264290328363383406439472497534556591
Mantle528571410835588127149165200
Cell55067141083417591106
Lymphoma,394072410833160118158196234293325338
Including42947241083155385100138177192230269
High-Risk45797241083445998136158196211237267
Subgroups,486272410833370109149170207245285311324
in520272410831553
the52717241083226095
ZUMA-2538272410833882136178200230
Study.39407341083335492132164174
J4135734108324
Clin41807341083405570108
Oncol430973410834786119156172
(Internet).4502734108318337293127149188223246265276
2022;JCO.21.02370.479873410833569102137150176217263275311343352388421456488522535
Available535373410834172105121136169208224259
from:39407441083184078136148
https://doi.org/10.1200/JCO.21.02370.4103744108338608412315016318921024528429931235037241043646950151354457460864466868973077678782385586489993296799910321045
Další39407617011061110135175200
literatura416276170110234982131165213247300334382
u45667617011051
autorky4640761701104598132185219267317
a39407725011046
na4008772501105199
www.onkologiecs.cz41307725011067139211232285339387439465518572598646690730755797842